Prosecution Insights
Last updated: April 19, 2026
Application No. 18/639,608

THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF

Final Rejection §103
Filed
Apr 18, 2024
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Regents Of The University Of Minnesota
OA Round
2 (Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
2y 4m
To Grant
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
818 granted / 1102 resolved
+14.2% vs TC avg
Strong +30% interview lift
Without
With
+30.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
58 currently pending
Career history
1160
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
15.0%
-25.0% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
47.6%
+7.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1102 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Claims Claims 1-20 and 23-25 are pending where claim 24 is new and drawn to group I. Claim 25 is drawn to withdrawn method claims. Claims 3, 4, 6, 8, 9, 11, 12, 14-16, 20 and 25 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 1, 2, 5, 7, 10, 13, 17-19, 23 and 24 is contained herein. Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 9/8/2025 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 12/8/2025. New Objections and Rejections Claim Objections Claim 18 is objected to because the instant claims possess non-elected subject matter. Applicant elected group I without traverse, drawn to compounds of the general formula (I). As stated in the Non Final office action, claim 18 contains a myriad of species such as the following: PNG media_image1.png 532 770 media_image1.png Greyscale PNG media_image2.png 168 222 media_image2.png Greyscale . These compounds have the limitation wherein Ra or b is selected from “alkanoyl”, R2 is substituted with “aryl” or unsubstituted completely. These limitations were not present in claim 1 at the time of initial examination. The examiner recommends that these species are removed from the claim. Appropriate correction is required. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 2, 5, 7, 10, 17, 19, and 23 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent 6,218,537. The instant claims may be drawn to the following compounds and compositions thereof: PNG media_image3.png 804 586 media_image3.png Greyscale PNG media_image4.png 556 590 media_image4.png Greyscale wherein the fluoro atom is replaced with other halogens such as Cl, Br, or I and other variables are defined as G = -CH, R1 = halo (excluding F) substituted phenyl, R2 = substituted phenyl, R3 = H, F = -NH, and A,B,D,E are selected from N and CH. Patent ‘537 teaches a myriad of compounds and compositions thereof such as those shown above wherein R1 = fluoro substituted phenyl (see col. 58, lines 40-65 for compounds and col. 40, lines 29-65 for compositions thereof). The difference as stated previously is the substitution for fluorine with other halogens on the phenyl ring at variable R1. However the document teaches that any halogen atom may be used as a substituent on the phenyl ring and are equivalent (see col. 3, lines 58-65, variable R4 being phenyl): PNG media_image5.png 660 560 media_image5.png Greyscale . Thus the claimed compounds would have been considered obvious over the prior art. Conclusion Claims 1, 2, 5, 7, 10, 17, 19, and 23 are rejected. Claims 13, 18, and 24 are objected to. Again note that species where A=B=G= -CH, E=D= N, R1 = R2 = phenyl, and F = -NH were searched and the full scope of formula I has not been searched to determine full patentability due to art of record in accordance with MPEP 803.02. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN E MCDOWELL/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Apr 18, 2024
Application Filed
Sep 04, 2025
Non-Final Rejection — §103
Dec 08, 2025
Response Filed
Feb 22, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599615
USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES
2y 5m to grant Granted Apr 14, 2026
Patent 12604600
Organic Electroluminescent Element And Novel Iridium Complex
2y 5m to grant Granted Apr 14, 2026
Patent 12559494
NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
2y 5m to grant Granted Feb 24, 2026
Patent 12552807
PCSK9 INHIBITORS AND METHODS OF USE THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent 12545665
CRYSTAL FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.3%)
2y 4m
Median Time to Grant
Moderate
PTA Risk
Based on 1102 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month